“…Additionally, LXR is known to elevate cholesterol levels in peripheral cells, the liver, and the intestine, which results in an overall net increase in cholesterol mobilization and catabolism, thus making LXR a pharmaceutical target for therapeutic intervention for the treatment of hypercholesterolemia and atherosclerosis. Indeed, several research groups identified agents that can reduce atherosclerosis without activating SREBP-1c or increasing hepatic lipogenesis, such as taurine, taurine, ethyl 2,4,6-trihydroxybenzoate, WAY-252623, and N,N-dimethyl-3β-hydroxy-cholenamide [32,35,36]. Indeed, sesamin enhances cholesterol efflux from RAW264.7 macrophages as reported by Liu et al [37].…”